Skip to content

IPF COMFORT Study for Chronic Cough

Search Clinical Trials

Trial Objectives


The IPF COMFORT Study is a clinical research study in patients with coughing attributed to Idiopathic Pulmonary Fibrosis. The investigational drug the study is testing is a once a day tablet called orvepitant. The cough in IPF may be caused by the airways becoming oversensitive, and it is hoped that orvepitant will reduce this over-sensitivity.
The purpose of the IPF COMFORT Study is to see if orvepitant reduces the severity and burden of coughing in people with IPF. The study will also test the safety of orvepitant, how the drug is absorbed and used within the body. Orvepitant is an investigational medicine. This means that it is not approved for sale, but it is but it is approved for use in clinical studies like this one.

Who Can Participate


People ages 40 and older who have been diagnosed with Idiopathic Pulmonary Fibrosis and have had a troublesome cough lasting for at least 8 weeks that has not responded to other treatments

Age: 40+ Gender Any

Estimated Time Commitment


Six study appointments over 17 weeks, with clinic visits every three to four weeks

Payment & Reimbursement


Payment Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Kaitlin Fier
303.270.2852

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


NeRRe Therapeutics Ltd

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required